By Counterforce Health Team in Natpara (parathyroid hormone) —

Getting Natpara (Parathyroid Hormone) Covered by Aetna CVS Health in Pennsylvania: 2026 Discontinuation Guide and Alternative Coverage

Answer Box: Natpara Coverage Status with Aetna CVS Health in Pennsylvania

Natpara (parathyroid hormone) is no longer available as Takeda discontinued manufacturing in December 2024, with the U.S. Special Use Program ending December 31, 2025. Aetna CVS Health now automatically denies new Natpara prescriptions due to lack of commercial supply. However, Pennsylvania patients have strong appeal rights through the state's new external review program, which overturns 50% of denials. For hypoparathyroidism treatment, focus on getting Yorvipath (the new FDA-approved alternative) or optimized calcium/calcitriol therapy covered instead.

First step today: Work with your endocrinologist to transition to Yorvipath or enhanced conventional therapy, then submit prior authorization through CVS Specialty Pharmacy with documented failure of standard calcium/vitamin D treatment.

Table of Contents

  1. Current Natpara Availability Status
  2. Aetna CVS Health Coverage Policies
  3. Alternative Treatment Coverage
  4. Prior Authorization Process
  5. Pennsylvania Appeal Rights
  6. Timeline and Expectations
  7. Required Documentation
  8. Cost-Saving Options
  9. When to Escalate
  10. FAQ

Current Natpara Availability Status

Natpara (parathyroid hormone) faced persistent manufacturing issues since its 2019 FDA recall, including rubber particle contamination and protein aggregation problems. Takeda announced in October 2022 that it would cease global production at the end of 2024.

The U.S. Special Use Program, which provided limited access to approximately 420 patients since September 2019, officially ended December 31, 2025. This means:

  • No new prescriptions can be filled
  • No commercial supply exists anywhere in the U.S.
  • All insurance denials for new starts are now automatic and appropriate
Note: If you were previously enrolled in the Special Use Program, you should have received transition guidance from Takeda and your endocrinologist about alternative treatments.

Aetna CVS Health Coverage Policies

Current Status for Natpara

All major insurers, including Aetna CVS Health, now automatically deny Natpara prescriptions due to the absence of commercial supply. This is not a coverage decision but a reflection of reality—the medication simply doesn't exist to dispense.

Coverage for Alternatives

Aetna CVS Health does cover hypoparathyroidism treatments through their standard prior authorization process:

Treatment Type Coverage Status Requirements
Yorvipath (new FDA-approved alternative) Covered with PA Endocrinologist prescription, documented conventional therapy failure
Calcitriol (active vitamin D) Usually covered May require step therapy through vitamin D2/D3 first
Calcium carbonate Typically covered Standard formulary medication
Conventional combination therapy Covered Calcium + vitamin D analogs

Alternative Treatment Coverage

Yorvipath (Palopegteriparatide)

The FDA approved Yorvipath in August 2024 as the first new parathyroid hormone replacement therapy since Natpara's original 2015 approval. This represents your best option for hormone replacement therapy.

Aetna CVS Health typically requires:

  • Confirmed hypoparathyroidism diagnosis
  • Documented inadequate response to optimized calcium and active vitamin D therapy
  • Prescribing endocrinologist
  • Regular monitoring plan

Enhanced Conventional Therapy

Most patients transition to optimized conventional treatment:

  • Calcium supplementation: 1,000-3,000 mg daily in divided doses
  • Active vitamin D: Calcitriol 0.25-2.0 mcg daily
  • Monitoring: Regular serum calcium, phosphorus, and 24-hour urine calcium

Prior Authorization Process

Submission Methods for CVS Specialty

CVS Specialty Pharmacy handles most hypoparathyroidism medications for Aetna members:

Method Contact Notes
E-prescribe NCPDP ID: 1466033 Preferred method
Phone 1-877-408-9742 For urgent coordination
Fax 1-877-645-4142 Include all PA documentation
Provider Portal CVS Caremark portal Track status online

Timeline Expectations

Plan Type Standard PA Expedited PA Appeal Deadline
Commercial 3-5 business days 72 hours 180 days
Medicare Advantage 72 hours 24 hours 60 days
Aetna Better Health PA 14 days Faster for urgent Varies

Source: Aetna prior authorization timelines

Pennsylvania Appeal Rights

Pennsylvania launched its Independent External Review program in January 2024, providing strong consumer protections for denied treatments.

Success Rates

In 2024, Pennsylvania's program overturned 50.1% of 517 eligible denials, with 259 successful appeals. This gives you a real chance if your alternative treatment is initially denied.

Process Overview

  1. Internal Appeal First: Complete Aetna's internal appeal process
  2. External Review: File with Pennsylvania Insurance Department within 4 months
  3. Independent Review: Third-party physicians review your case
  4. Binding Decision: If overturned, Aetna must provide coverage

Timeline for External Review

Step Standard Timeline Expedited Timeline
PID processes request 1 business day 24 hours
Insurer eligibility check 5 business days 24 hours
IRO assignment 1 business day 24 hours
Submit additional info 15 days after assignment Concurrent
Final decision 45 days from assignment 72 hours

Contact: Pennsylvania Insurance Department at 1-877-881-6388 or pa.gov external review portal

Required Documentation

For Yorvipath Prior Authorization

  • Diagnosis confirmation: ICD-10 code E20.9 (hypoparathyroidism)
  • Laboratory values:
    • Baseline serum calcium >7.5 mg/dL
    • Low or inappropriately normal PTH levels
    • Normal magnesium and 25-hydroxyvitamin D
  • Prior therapy documentation:
    • Adequate trial of calcium supplementation (≥1,000 mg/day)
    • Active vitamin D therapy trial with doses and duration
    • Documentation of inadequate response or intolerance
  • Specialist requirement: Endocrinologist prescription preferred

For Enhanced Conventional Therapy

  • Same diagnostic requirements as above
  • Step therapy documentation if calcitriol is non-formulary
  • Monitoring plan for calcium levels and kidney function
Clinician Corner: When documenting prior therapy failures, include specific doses, duration of treatment, and objective measures of inadequate response (persistent hypocalcemia, inability to maintain target calcium levels, or documented intolerance symptoms).

Cost-Saving Options

Manufacturer Support

  • Yorvipath: Check with Ascendis Pharma for patient assistance programs
  • Calcitriol: Generic versions typically have lower copays

Pennsylvania-Specific Resources

  • CHIP and Medicaid: Enhanced coverage for qualifying families
  • Patient Advocate Foundation: Free case management for insurance issues
  • Pennsylvania Health Law Project: Free legal assistance with appeals

When to Escalate

Pennsylvania Insurance Department

If you're experiencing coverage issues beyond normal appeals:

Contact: 1-877-881-6388
Online: pa.gov insurance consumer services
What to include: Policy details, denial letters, medical records, timeline of communications

Federal Options

For ERISA plans (employer self-funded):

  • U.S. Department of Labor Employee Benefits Security Administration
  • File complaints about improper claim handling or ERISA violations

FAQ

Q: Can I still get Natpara if I was previously on it?
A: No. The Special Use Program ended December 31, 2025, and no commercial supply exists. You must transition to alternative treatments.

Q: How long does Aetna CVS Health take for specialty medication PA in Pennsylvania?
A: Standard decisions typically take 3-5 business days for commercial plans, 72 hours for Medicare Advantage. Expedited reviews are available for urgent medical needs.

Q: What if Yorvipath is denied as "experimental"?
A: Yorvipath received full FDA approval in August 2024. Appeal with the FDA approval letter and clinical evidence. Pennsylvania's external review program has a 50% success rate for overturning such denials.

Q: Does step therapy apply to hypoparathyroidism medications?
A: Yes, Aetna typically requires documented failure of conventional calcium and vitamin D therapy before approving hormone replacement options like Yorvipath.

Q: Can I request expedited review for hypoparathyroidism treatment?
A: Yes, if your doctor certifies that delays could cause serious health consequences. Submit the Physician Certification Form with your expedited request.

Q: What counts as "adequate trial" of conventional therapy?
A: Typically 3-6 months of optimized calcium (≥1,000 mg daily) plus active vitamin D at appropriate doses, with documented persistent hypocalcemia or intolerance.

At Counterforce Health, we help patients and clinicians navigate complex insurance approvals by turning denials into targeted, evidence-backed appeals. Our platform analyzes denial letters and payer policies to draft point-by-point rebuttals that align with each plan's specific requirements, pulling the right clinical evidence and regulatory citations to support your case.

From our advocates: "When transitioning from discontinued Natpara, we've seen success by framing the request around 'continuation of established therapy' rather than 'new treatment initiation.' Document the patient's previous response to hormone replacement and emphasize that conventional therapy alone was previously inadequate—this helps establish medical necessity for the new alternative."

Disclaimer

This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies vary by plan and change frequently. Always verify current requirements with Aetna CVS Health directly and consult your healthcare provider for medical decisions. For official Pennsylvania insurance information and complaint processes, visit pa.gov or call 1-877-881-6388.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.